Larazotide acetate alters the paracellular permeability of the GI tract to inhibit transport of gluten peptides into the lamina propria, according to the report. When compared to a placebo, the primary results of the outcome were reduced symptoms of diarrhea, indigestion and abdominal pain as measured by the Celiac Disease Gastrointestinal Symptom Rating Scale.
If approved by the FDA, the drug would not be a solo treatment, but rather a complementary strategy alongside current dietary strategies.
More articles on gastroenterology:
6 gastroenterologists making headlines
Solos Endoscopy to expand device distribution to Canada
Does sigmoidoscopy fill a colorectal cancer screening niche?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
